Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries

Spinal Cord Injury Clinical Trial

Official title:

Intrathecal Administration (Pattern 100/3) of Expanded Autologous Adult Bone Marrow Mesenchymal Stem Cells in Established Chronic Spinal Cord Injuries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02570932
• Other study ID #: CME-LEM3
• Secondary ID: 2014-005613-24
• Status: Completed
• Phase: Phase 2
• First received: October 2, 2015
• Last updated: April 3, 2018
• Start date: July 2015
• Est. completion date: December 4, 2017

Study information

• Verified date: April 2018
• Source: Puerta de Hierro University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to analyze the potential clinical efficacy of intrathecal administration, in the subarachnoid space, of in vitro expanded autologous adult bone marrow mesenchymal stem cells in the treatment of patients with established chronic spinal cord injury (LEM).

Description:

This is a clinical trial phase II, single-center, non-randomized, uncontrolled, open prospective follow-up of a cohort of patients with chronic spinal cord injury.

Patients are treated with repeated administrations of in vitro expanded autologous adult bone marrow mesenchymal stem cells.

The expanded cells are administered in the subarachnoid space by lumbar puncture. The minimum duration of the follow-up period for each patient is 10 months after the first administration.

The study duration is 24 months, that include recruiting, treatment and follow period for all patients. For each patient at the first day will be administered the first cellular doses, then 3 doses will be administrated every 3 months. At the end of the clinical trial, a completed check of all obtained parameters will be performed.

It is considered Day 1 for each patient the first day of the first cell administration. The remaining 2 doses will be administered at intervals of 3 months from the first administration (of the treatment period after, months 4 and 7). At the end of the study will be performed a full assessment of the variables collected along the study trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: December 4, 2017
• Est. primary completion date: December 4, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Spinal cord injury (Level A, B, C or D in ASIA scales), clinically stable for at least 6 months prior to study start.

2. Previous studies of Neurophysiology, MRI and Urology to allow useful baseline, in order that they can be compared with the same scans following treatment, and to obtain objective data of potential efficacy.

3. Age between 18 and 70 years.

4. Men and women of childbearing age must compromise to use contraceptives from the time at which the removal of cells from the bone marrow is performed until 6 months after the Mesenchymal Stem Cells (MSC) last administration by lumbar puncture.

5. Possibility of follow up and ability to perform ambulatory physical therapy throughout all treatment period.

6. Written informed consent, according to the law in force.

7. Hematologic, creatinine, Serum glutamic oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic transaminase (SGPT) parameters, within the normal range, according to laboratory standards. However, slight modifications that are considered significant in the context of treatment to be performed, according to the criterion of the research team, are accepted.

Exclusion Criteria:

1. Age below 18 years or above 70.

2. Pregnancy or lactation.

3. Current neoplastic disease or in the previous 5 years (diagnosed or treated).

4. Patients with systemic disease that represents an added risk to treatment.

5. Alterations in the genetic study performed to discard risk cell transformation in the expansion process.

6. Patients with doubts about possible cooperation in the maintenance physical therapy or in the controls carried out during the study

7. Neurodegenerative disease added.

8. History of substance abuse, psychiatric disease or allergy to protein products used in the process of cell expansion.

9. Positive serology for HIV and syphilis.

10. Active Hepatitis B or Hepatitis C, according to serology analysis.

11. If in the opinion of the researcher there is some other reason why the patient is not considered candidate for the study.

Related Conditions & MeSH terms

• Spinal Cord Injuries
• Spinal Cord Injury
• Wounds and Injuries

Intervention

Biological:
• Autologous Mesenchymal Bone Marrow Cell
Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow. Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration

Locations

Country	Name	City	State
Spain	Hospital Puerta de Hierro	Majadahonda	Madrid

Sponsors (1)

Lead Sponsor	Collaborator
Puerta de Hierro University Hospital

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in IANR-SCIFRS score are considerate for the motor and sensory functions evaluation.	Efficacy evaluation by measuring the change in motor and sensory functions by using the international Association of Neurorestoratology-Spinal Cord Injury Functional Rating Scale (IANR-SCIFRS). This scale includes 9 categories with 16 items in total (plus one optional category).; The maximum possible score is 48; the lowest possible score is 0.	from baseline until the end of the follow up period (24 months)
Secondary	Neurotrophic factors levels in Cerebrospinal fluid (CSF) and/ or Number of Adverse Events related to treatment	The clinical evaluation of possible adverse effects is performed throughout the entire study duration and will be measured by descriptive analysis	from baseline to 24 months
Secondary	Changes in PENN score are considerate for the motor and sensory functions evaluation	Efficacy evaluation by measuring the change in motor and sensory functions by using the Penn Spasm Frequency Scale that is Composed of 2-parts: the first is a self-report measure with items on 5-point scales developed to augment clinical ratings of spasticity and provides a more comprehensive assessment of spasticity	from baseline until the end of the follow up period (24 months)
Secondary	Changes in VAS score are considerate for quantification of pain	Efficacy evaluation by measuring the change in pain by using the visual analogue scale (VAS). The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks, depending on his feel of pain.	from baseline until the end of the follow up period (24 months)
Secondary	Changes in BDS score are considerate for the Assessment of the functional status	Efficacy evaluation by measuring the change in the Blepharospasm Disability Scale (BDS)	from baseline until the end of the follow up period (24 months)
Secondary	Changes in GEFFNER score are considerate for the Assessment of the functional status	Efficacy evaluation by measuring the change in the GEFFNER score	from baseline until the end of the follow up period (24 months)